CORRECT(8/31): Eli Lilly Prasugrel Risk Cut By 40%, Not 13.2%
Wednesday September 3rd, 2008 / 13h26
The study presented Sunday at the European Society of Cardiology meeting in Munich, Germany, found that diabetics who had experienced a heart attack were 40%, not 13.2%, less likely to have a subsequent attack if they took prasugrel, compared with those who took Plavix. By contrast, those who took Plavix, which Sanofi-Aventis co-markets with Bristol-Myers Squibb Co. (BMY) and had heart attacks were 13.2%, not reduced their risk by 13.2%, compared with 8.2% for those treated with prasugrel. In non-diabetics, however, the risk rates for both treatments didn't differ much. It was 7.2%, not 8.7%, for prasugrel and 8.7%, not 7.2%, for Plavix, researchers found. ("=Eli Lilly's Prasugrel More Beneficial For Diabetics - Study" published at 1256 GMT Aug. 31, contained percentage errors in the second, fourth and fifth paragraph.) Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/al?rnd=AvSeyy9xnxfM2x48pEC5Ew%3D%3D. You can use this link on the day this article is published and the following day.
Sanofi-Aventis est le 1er groupe pharmaceutique européen. Le CA par famille de produits se répartit comme suit : - produits pharmaceutiques (90,1%) :...
